Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $232000.0.

  • Lisata Therapeutics' Share-based Compensation fell 2905.2% to $232000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 972.5%. This contributed to the annual value of $1.7 million for FY2024, which is 1889.11% down from last year.
  • Latest data reveals that Lisata Therapeutics reported Share-based Compensation of $232000.0 as of Q3 2025, which was down 2905.2% from $239000.0 recorded in Q2 2025.
  • In the past 5 years, Lisata Therapeutics' Share-based Compensation registered a high of $675000.0 during Q1 2023, and its lowest value of $232000.0 during Q3 2025.
  • Its 3-year average for Share-based Compensation is $426545.5, with a median of $454000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Lisata Therapeutics' Share-based Compensation was 3424.95% (2024), while the steepest drop was 5934.82% (2024).
  • Quarter analysis of 3 years shows Lisata Therapeutics' Share-based Compensation stood at $473000.0 in 2023, then surged by 34.25% to $635000.0 in 2024, then plummeted by 63.46% to $232000.0 in 2025.
  • Its last three reported values are $232000.0 in Q3 2025, $239000.0 for Q2 2025, and $530000.0 during Q1 2025.